~~<i id='95B930F5DC'><strike id='95B930F5DC'><tt id='95B930F5DC'><pre id='95B930F5DC'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

leisure time

author：explore 2025-09-27 10:06:18 - browse：9

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Erich Jarvis studies song birds to learn about human stuttering

Wikipedia

focus

hotspot

focus

knowledge

StephanieW.EdmondsandGinnyL.Ryanarebothdoctors.Edmonds,aregisterednurse,hasaPh.D.;Ryanisatraditional

WSS

Device maker Teleflex to acquire urology company for $600M

CDC Director Mandy Cohen on transparency, trust, and health

CRISPR technology availability, affordability needs to be expanded

In the gardens at Boston Children's Hospital, families find sanctuary

Pfizer, Moderna say biotech, pharma drug development is a sprint

With Wegovy coverage, Medicare patients may face high costs

explore

leisure time

Wikipedia

In age of alternative facts, a scholarly course on calling out crap

Erich Jarvis studies song birds to learn about human stuttering

Alkermes shareholders re

Will the FTC rein in IQVIA's health data empire?

BioMarin wins approval for gene therapy to treat hemophilia A

Search called off for baby washed away in Pennsylvania flash flood

State Dept. review finds Biden bears some blame for Afghanistan failures

Diabetes management: Digital health tools fall short, study says

Hollywood unions extend contract negotiations for actors

Testing GLP

focus

Biotech investment managers search for lucrative opportunities

Democrats decry new health bill for going easy on private equity

A new crop of companies is reshaping the health data economy

Former reverend arrested for allegedly killing 8

Testing GLP

Search called off for baby washed away in Pennsylvania flash flood

hotspot

hotspot

focus

knowledge